[go: up one dir, main page]

WO2006008173A2 - Formulations pharmaceutiques - Google Patents

Formulations pharmaceutiques Download PDF

Info

Publication number
WO2006008173A2
WO2006008173A2 PCT/EP2005/007991 EP2005007991W WO2006008173A2 WO 2006008173 A2 WO2006008173 A2 WO 2006008173A2 EP 2005007991 W EP2005007991 W EP 2005007991W WO 2006008173 A2 WO2006008173 A2 WO 2006008173A2
Authority
WO
WIPO (PCT)
Prior art keywords
hydroxy
salt
active agent
pharmaceutical formulation
pharmaceutically active
Prior art date
Application number
PCT/EP2005/007991
Other languages
English (en)
Other versions
WO2006008173A3 (fr
Inventor
Michael Simon Anson
Derek Leslie Crookes
Harish Shivprasad Trivedi
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of WO2006008173A2 publication Critical patent/WO2006008173A2/fr
Publication of WO2006008173A3 publication Critical patent/WO2006008173A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Definitions

  • the present invention is concerned with pharmaceutical formulations of active agents, in particular salts of polymeric sugars with pharmaceutically active agents useful for administration by inhalation, e.g. in the prophylaxis and treatment of respiratory diseases, salts of polymeric sugars with pharmaceutically active agents, processes for their preparation and their use in medicine.
  • Pharmaceutically active agents for the prophylaxis and treatment of respiratory diseases are commonly administered by inhalation of particle dusts or mists which may be generated by means of various types of metered dose pressurised aerosols, dry powder inhalers, nebulisers or insufflators.
  • Inhalation of drugs to the lungs or the nasal mucosa is also a useful route for administration of other pharmaceutically active agents, in particular because this route can result in rapid onset of action of the active agent.
  • Dry powder inhalers typically use a carrier such as lactose as a diluent to allow precise metering of the dose and to facilitate dispersion of the active agent on inhalation by the patient.
  • a carrier such as lactose
  • Some lactose formulations can be prone to degradation on storage which can result in reduction of the the dose delivered to the lungs thus requiring careful control of the shelf life.
  • dry powder formulations exhibit stability with relation to the quantity of particles of this size that they contain.
  • salts of respiratory drugs are provided in the form of a crystalline salt, as crystalline salts are generally believed to have favourable physical properties such as defined hygroscopicity and aqueous solubility and/or good stability.
  • crystalline salts are generally believed to have favourable physical properties such as defined hygroscopicity and aqueous solubility and/or good stability.
  • the ⁇ 2 - adrenoreceptor agonist salmeterol is currently formulated for administration as a crystalline xinafoate salt.
  • the present invention is based on the finding that an amorphous salt of salmeterol with hyaluronic acid exhibits surprisingly advantageous properties, particularly when formulated as a formulation, e.g. a dry powder formulation, adapted for administration by inhalation.
  • a formulation e.g. a dry powder formulation
  • biodegradable polymeric sugars bearing acid or base functionality include hyaluronic acid, heparin/heparan sulfate, dermatan sulfate, chondroitin sulfate, keratin sulfate, alginic acid and salts thereof.
  • Hyaluronic acid (CAS registry number 9004-61-9), also known as hyaluronan, is a naturally occurring polymeric sugar with a molecular weight of about 2x10 5 to 2x10 6 Da which is formed of repeating disaccharide units of glucuronic acid and N- acetylglucosamine.
  • the chemical representations of hyaluronic acid and the other polymeric sugars given below are for purposes of illustration only, and show the repeating disaccharide units present in the polymeric chain.
  • Hyaluronic acid is widely found in connective tissues of humans and animals, e.g. skin, vitreous and aqueous humor, umbilical cord and synovial fluid. Hyaluronic acid has been used as a medicinal excipient, for example in biomaterials and viscoelastic solutions for intra-articular and ophthalmic delivery. Hyaluronic acid is available from a number of commercial sources.
  • Heparin (CAS registry number 9005-49-6) and heparan sulfate (CAS registry number 9050-30-0) both have the same basic structure of repeating disaccharides units of glucuronic acid and ⁇ /-acetylglucosamine. Both polymers contain numerous variations of sulfonation and L-epimerisation. They are commonly differentiated by the proportion of N- sulfonation, heparan sulfate generally being considered to have less than 50% and heparin generally greater than 70%. Individual chains can reach 1x10 5 t)a but are normally below 5x10 4 Da.
  • Heparin is widely known for its anti-coagulant action, based on its binding with antithrombin III. Heparin is available from a number of commercial sources.
  • Dermatan sulfate (CAS registry number 24967-94-0) is another example of a naturally occurring polymeric sugar, having a molecular weight of about 1x10 4 to 4x10 4 Da, it is formed of repeating disaccharide units of hexuronic acid (either glucuronic acid or its epimerised form iduronic acid, both forms can be found in one individual carbohydrate chain) and ⁇ -acetylgalactosamine.
  • the disaccharide is often sulfonated in position 2 of the iduronic acid or position 4 of ⁇ -acetylgalactosamine. Dermatan sulfate is available from a number of commercial sources.
  • Chondroitin sulfate (CAS registry number 9007-28-7) consists of disaccharides containing glucuronic acid and / ⁇ -acetylgalactosamine, it is the most common glycosaminoglycan form found in articular cartilage. The molecular weight of a single chain is typically in the region of 1x10 4 to 2x10 4 Da. The component disaccharides are often sulfonated at position 4 or 6 of the / ⁇ -acetylgalactosamine, although unsulfonated, di- and tri-sulfonated forms have been observed. Chondroitin sulfate is available from a number of commercial sources.
  • Keratan sulfate (CAS registry number 9056-36-4) consists of repeating units of galactose and /V-acetylglucosamine, demonstrating variation in molecular weight from around 4x10 3 to 2x10 4 Da; variation in the degree of sulfonation is also observed. Certain forms of keratin sulfate may contain fucose and /V-acetyl neuraminic acid groups in their chains, while chain branching is also known to occur. Keratan sulfate is available from a number of commercial sources.
  • Alginic acid (CAS registry number 9005-32-7) is a polysaccharide which is obtained from seaweed. Alginic acid contains mannuronic acid and guluronic acid residues, the proportions of each being dependent upon the species of seaweed from which it is extracted. The two sugar monomers often occur in blocks of up to twenty units, the number and length of the blocks being an important factor in determining the physical properties of the chains.
  • alginic acid A number of salt forms of alginic acid are known (not all of which are soluble in water) for example sodium alginate (CAS registry number 9005-38-3).
  • International Patent Application WO 95/26735 discloses the use of hyaluronic acid for the treatment of respiratory disorders.
  • International Patent Application WO 01/93846 discloses the use of polysaccharides, including hyaluronic acid, for the prophylaxis and treatment of elastic fiber injury in mammals.
  • International Patent Application WO 02/102317 discloses the use of hyaluronic acid for the treatment of tissue kallikrein- induced bronchoconstriction.
  • US Patent Application 2003/0171332 describes the use of aerosolised polysaccharides, including hyaluronic acid, for the treatment of respiratory conditions associated with tissue kallikrein-induced bronchoconstriction. This application only exemplifies solutions of hyaluronic acid for administration by nebulisation, it does not exemplify solid particulate formulations for inhalation.
  • Japanese Patent Application 11171761 discloses inhalation formulations comprising drug microparticles, e.g. beclomethasone propionate, coated with a biodegradeable and bioadhesive polymer e.g. sodium hyaluronate. Journal of Controlled Release, Sept 4, 2003, 91(3), 385-94 describes the preparation of a dry powder for inhalation comprising co-spray drying sodium hyaluronate and human insulin.
  • Japanese Patent Application 11080032 discloses pharmaceutical compositions comprising a basic drug and an acidic polysaccharide.
  • International Patent Application WO 00/08061 discloses cosmetic and pharmaceutical compositions comprising amino acid salts of hyaluronic acid e.g. lysine hyaluronate.
  • International Patent Application WO 98/17285 discloses compositions for topical administration comprising a neutral salt of hyaluronic acid and a basic anaesthetic, e.g. benzydamine or bupivacaine, it does not disclose solid particulate formulations of these salts for inhalation.
  • Ophthalmic Research, 1998, 30(2), 101-106 discloses timolol and pilocarpine hyaluronate salts for the treatment of ocular hypertension.
  • a pharmaceutical formulation adapted for administration by inhalation comprising a salt of a biodegradable polymeric sugar comprising acidic groups and a pharmaceutically active agent comprising one or more basic groups, and a pharmaceutically acceptable carrier or diluent.
  • the salt of a biodegradable polymeric sugar comprising acidic groups and a pharmaceutically active agent comprising one or more basic groups is hereinafter referred to as a "salt of the invention”.
  • Biodegradable polymeric sugars comprising acidic groups which may be used to form the salts of the invention include hyaluronic acid, chondroitin sulfate e.g. chondroitin sulfate A, B or C, alginic acid, keratin sulfate and heparan sulfate. As mentioned above these sugars comprise carboxylic acid and/or sulfonic acid groups.
  • the acidic groups are preferably carboxylic acid groups.
  • Pharmaceutically active agents which are suitable for formulation as salts according to the invention include agents comprising basic group(s) having a pKa >6, preferably a pKa of 7-12 in the case of sugars comprising carboxylic acid groups (e.g. hyaluronic acid and alginic acid); and a pKa >4, preferably a pKa of 4-12 in the case of sugars comprising sulfonic acid groups (e.g. keratan sulfate); and a pKa >4, preferably a pKa of 4-12 in the case of sugars comprising both sulfonic acid groups and carboxylic acid groups (e.g.
  • the preferred pKa of the basic group(s) of the pharmaceutically active agent may be determined by reference to the strength of the acid.
  • Pharmaceutically active agents containing one or more amine groups are preferred.
  • the invention also provides a salt of a biodegradable polymeric sugar comprising acidic groups and a pharmaceutically active agent containing one or more amine groups.
  • Specific pharmaceutically active agents which may be mentioned include ⁇ 2 - adrenoreceptor agonists, anti-inflammatory agents (e.g. NSAIDs or PDE-4 inhibitors), anticholinergic agents (e.g. M 1 , M 2 , M 1 ZM 2 or M 3 receptor antagonists), antiinfective agents (e.g. antibiotics, antivirals) and antihistamines.
  • anti-inflammatory agents e.g. NSAIDs or PDE-4 inhibitors
  • anticholinergic agents e.g. M 1 , M 2 , M 1 ZM 2 or M 3 receptor antagonists
  • antiinfective agents e.g. antibiotics, antivirals
  • antihistamines e.g. antibiotics, antivirals
  • ⁇ 2 -adrenoreceptor agonists include salmeterol, (R)-salmeterol, salbutamol, (R)-salbutamol, formoterol, (R,R)-formoterol, fenoterol, etanterol, naminterol, clenbuterol, pirbuterol, flerobuterol, reproterol, bambuterol and terbutaline.
  • Other examples include those described in International Patent Applications WO
  • ⁇ 2 -adrenoreceptor agonists include QAB-149, LAS-32521 , [R-(R * ,R * )]-8-hydroxy-5-
  • Ar 1 is 4-amino-3,5-dichlorophenyl or 3-formylamino-4-hydroxyphenyl, and the stereochemistry at * C and ** C is (RS) and (RS), (R) and (R), (S) and (S), (R) and (S), or (S) and (R), e.g ⁇ /- ⁇ 2-[4-((R)-2-Hydroxy-2-phenylethylamino)phenyl]ethyl ⁇ -(R)-2-hydroxy-2- (3-formamido-4-hydroxyphenyl) ethylamine;
  • NSAIDs examples include phosphodiesterase (PDE) inhibitors (e.g. theophylline, PDE4 inhibitors or mixed PDE3/PDE4 inhibitors), leukotriene antagonists, inhibitors of leukotriene synthesis, iNOS inhibitors, tryptase and elastase inhibitors, beta-2 integrin antagonists and adenosine receptor agonists or antagonists (e.g. adenosine 2a agonists), cytokine antagonists (e.g. chemokine antagonists) or inhibitors of cytokine synthesis.
  • PDE phosphodiesterase
  • leukotriene antagonists inhibitors of leukotriene synthesis
  • iNOS inhibitors tryptase and elastase inhibitors
  • beta-2 integrin antagonists e.g. adenosine 2a agonists
  • cytokine antagonists e.g. chemokine antagonists
  • antihistamines include any one or more of the numerous antagonists known which inhibit H 1 -receptors, and are safe for human use.
  • First generation antagonists include derivatives of ethanolamines, ethylenediamines, and alkylamines, e.g. diphenylhydramine, pyrilamine, clemastine, chlropheniramine.
  • Second generation antagonists which are non-sedating, include loratidine, desloratidine, terfenadine, astemizole, acrivastine, azelastine, levocetirizine fexofenadine and cetirizine.
  • antimuscarinic antagonists examples include 2-[(S)-1-(8-methylaminooctyl)-pyrrolidin-3- yl]-2,2-diphenylacetamide.
  • salts of the invention include salts of amine containing pharmaceutically active agents, e.g. primary, secondary or tertiary amine containing pharmaceutically active agents.
  • pharmaceutically active agents are amine containing ⁇ 2 -adrenoreceptor agonists.
  • a particular salt of the invention is salmeterol hyaluronate.
  • salts of the invention which are of interest are salbutamol hyaluronate,
  • compositions containing salts of the invention may also comprise one or more other pharmaceutically active agents, e.g. selected from the lists defined above.
  • Formulations containing salts of ⁇ 2 -adrenoreceptor agonists may desirably also contain a glucocorticoid receptor agonist.
  • glucucorticoid agonists include steroids such as budesonide, ciclesonide, triamcinoline acetonide and beclomethasone dipropionate.
  • glucucorticoid agonists include steroids such as fluticasone propionate, 6 ⁇ ,9 ⁇ -difluoro-11 ⁇ -hydroxy-16 ⁇ -methyl-17 ⁇ -[(4-methyl-1 ,3- thiazole-5-carbonyl)oxy]-3-oxo-androsta-1 ,4-diene-17 ⁇ -carbothioic acid S-fluoromethyl ester and 6 ⁇ ,9 ⁇ -difluoro-17 ⁇ -[(2-furanylcarbonyl)oxy]-11 ⁇ -hydroxy-16 ⁇ -methyl-3-oxo- androsta-1 ,4-diene-17 ⁇ -carbothioic acid S-fluoromethyl ester.
  • steroids such as fluticasone propionate, 6 ⁇ ,9 ⁇ -difluoro-11 ⁇ -hydroxy-16 ⁇ -methyl-17 ⁇ -[(4-methyl-1 ,3- thiazole-5-carbonyl)oxy]-3-oxo-androsta-1 ,4-diene-17 ⁇ -carbothioic acid S-
  • the biodegradable polymeric sugar when employed according to the invention may typically have a molecular weight of around 10 4 -10 6 Da.
  • a particular biodegradable polymeric sugar for use in the invention is hyaluronic acid.
  • the maximum possible loading of the pharmaceutical active agent onto the biodegradable polymeric sugar can be determined theoretically by reference to the specific agent and sugar.
  • the maximum loading is around 2.5mmol/g (i.e. 2.5 mmol of active agent per g of sugar).
  • the polymeric sugar is alginic acid
  • the maximum loading is around 5mmol/g.
  • the polymeric sugar is chondroitin sulfate or dermatan sulfate
  • the maximum loading is around 4mmol/g.
  • the polymeric sugar is keratan sulfate the maximum loading is around 2 mmol/g.
  • the maximum loading is around 6 mmol/g.
  • a loading of less than maximum is employed e.g. 50-75% of maximum.
  • Lower loadings of drug e.g. of about 25% of maximum may be particularly advantageous for highly potent drugs.
  • the maximum loading capacity of pharmaceutically active agent in the salts of the invention is around 55% w/w (i.e. weight of pharmaceutically active agent / weight of salt).
  • a drug substance of molecular weight of approximately 500 Da loadings are typically between 5—40% w/w.
  • Lower loadings of drug e.g. of about 10% w/w may be particularly advantageous for highly potent drugs.
  • the pharmaceutical formulations and salts of the invention have use in the prophylaxis and treatment of diseases treatable by administration of an active agent by inhalation e.g. respiratory diseases.
  • diseases treatable by administration of an active agent by inhalation e.g. respiratory diseases.
  • diseases associated with reversible airways obstruction such as asthma, chronic obstructive pulmonary diseases (COPD) (e.g. chronic and whez bronchitis, emphysema), respiratory tract infection and upper respiratory tract disease (e.g. rhinitis, including seasonal and allergic rhinitis).
  • COPD chronic obstructive pulmonary diseases
  • rhinitis e.g. chronic and whez bronchitis, emphysema
  • the present invention provides a method for the prophylaxis or treatment of disease in a mammal which comprises administration by inhalation of a therapeutically effective amount of a pharmaceutical formulation or a salt according to the invention.
  • the invention also provides a method for the prophylaxis or treatment of a respiratory disease, which comprises administration of a therapeutically effective amount of a pharmaceutical formulation or a salt of the invention.
  • the present invention provides such a method for the prophylaxis or treatment of a disease associated with reversible airways obstruction such as asthma, chronic obstructive pulmonary disease (COPD), respiratory tract infection or upper respiratory tract disease.
  • COPD chronic obstructive pulmonary disease
  • a pharmaceutical formulation or a salt of the invention for use in medical therapy, particularly, for use in the prophylaxis or treatment of a respiratory disease in a mammal, such as a human.
  • a pharmaceutical formulation or a salt of the invention for the prophylaxis or treatment of a disease associated with reversible airways obstruction such as asthma, chronic obstructive pulmonary disease (COPD), respiratory tract infection or upper respiratory tract disease.
  • COPD chronic obstructive pulmonary disease
  • the present invention also provides the use of a pharmaceutical formulation or a salt of the invention in the manufacture of a medicament adapted for administration by inhalation.
  • the invention also provides the use of a pharmaceutical formulation or a salt of the invention in the manufacture of a medicament for the prophylaxis or treatment of a respiratory disease, for example a disease associated with reversible airways obstruction such as asthma, chronic obstructive pulmonary disease (COPD), respiratory tract infection or upper respiratory tract disease.
  • a respiratory disease for example a disease associated with reversible airways obstruction such as asthma, chronic obstructive pulmonary disease (COPD), respiratory tract infection or upper respiratory tract disease.
  • COPD chronic obstructive pulmonary disease
  • the pharmaceutical formulations and salts of the invention may be formed with pharmaceutically active agents, such as morphine and codiene, which treat non ⁇ respiratory conditions for which administration by inhalation is beneficial e.g. to achieve rapid delivery to the system.
  • pharmaceutically active agents such as morphine and codiene
  • the amount of the salt of the invention which is required to achieve a therapeutic effect will, of course, vary with the particular active agent the subject under treatment, and the particular disorder or disease being treated.
  • the salts of the invention may typically be administered by inhalation at a dose of from O.OOOSmg to 10 mg, preferably 0.02mg to 2mg.
  • the dose range for adult humans is generally from 0.0005 mg to 5mg per day and preferably 0.01 mg to 1mg per day depending on the loading of active agent in the salt.
  • the amount of polymeric sugar which is administered to a human is such that it does not have any pharmacological effect, especially when the polymeric sugar is hyaluronic acid.
  • a salt of the invention While it is possible for a salt of the invention to be administered alone, it is preferable to present it as a pharmaceutical formulation.
  • Fine particle dusts or mists which may be generated by means of various types of metered dose pressurised aerosols, nebulisers or insufflators, the most suitable route of generation may depend upon, for example, the condition and disorder of the patient.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the salt of the invention into association with the carrier which may contain one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the salt of the invention with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
  • the pharmaceutical formulations and salts of the invention are preferably formulated as dry powder compositions for topical delivery to the lung by inhalation.
  • Dry powder compositions may, for example, be presented in capsules and cartridges of for example gelatine, or blisters of for example laminated aluminium foil, for use in an inhaler or insufflator.
  • Formulations generally contain a powder mix for inhalation of the salt of the invention and a suitable powder base (carrier substance) such as lactose or glticose. Use of lactose is preferred.
  • the salt of the invention may be presented without excipients.
  • Packaging of the formulation may be suitable for unit dose or multi-dose delivery. In the case of multi-dose delivery, the formulation can be pre-metered (e.g.
  • DiskusTM see GB 2242134 or DiskhalerTM, see GB 2178965, 2129691 and 2169265) or metered in use (e.g. as in TurbuhalerTM, see EP 69715 or EP237507).
  • An example of a unit-dose device is RotahalerTM (see GB 2064336).
  • the DiskusTM inhalation device comprises an elongate strip formed from a base sheet having a plurality of recesses spaced along its length and a lid sheet hermetically but peelably sealed thereto to define a plurality of containers, each container having therein an inhalable formulation containing a salt of the invention preferably combined with lactose.
  • the strip is sufficiently flexible to be wound into a roll.
  • the lid sheet and base sheet will preferably have leading end portions which are not sealed to one another and at least one of the said leading end portions is constructed to be attached to a winding means. Also, preferably the hermetic seal between the base and lid sheets extends over their whole width.
  • the lid sheet may preferably be peeled from the base sheet in a longitudinal direction from a first end of the said base sheet.
  • the formulation may be presented if desired together with one or more other therapeutic agents in an inhalation device wherein the individual therapeutic agents are administrable simultaneously but are stored separately (or wholly or partly stored separately for triple combinations), e.g. in separate pharmaceutical compositions, for example as described in WO 03/061743.
  • Each capsule, cartridge, pouch or blister may typically contain between 1 ⁇ g-3mg e.g. 10- 500 ⁇ g of the salt of the invention optionally in combination with another therapeutically active ingredient and optionally together with one or more carriers.
  • Spray compositions for topical delivery to the lung by inhalation may also be formulated as suspensions or as aerosols delivered from pressurised packs, such as a metered dose inhaler, with the use of a suitable liquefied propellant.
  • Aerosol compositions suitable for inhalation can be either a suspension or a solution and generally contain the salt of the invention optionally in combination with another therapeutically active agent and a suitable propellant such as a fluorocarbon or hydrogen-containing chlorofluorocarbon or mixtures thereof, particularly hydrofluoroalkanes, e.g.
  • the aerosol composition may be excipient free or may optionally contain additional formulation excipients well known in the art such as surfactants e.g. oleic acid or lecithin and cosolvents e.g. ethanol. Pressurised formulations will generally be retained in a canister (e.g.
  • Medicaments for administration by inhalation desirably have a controlled particle size.
  • the optimum aerodynamic particle size for inhalation into the bronchial system is usually 1-1 O ⁇ m, preferably 2-5 ⁇ m. Particles having a size above 20 ⁇ m are generally too large when inhaled to reach the small airways.
  • the particles of the salts of the invention may be size reduced by conventional means e.g. by micronisation or spray dried from a solution to yield particles of the desired size (i.e. mass median diameter (MMD) of 1-1 O ⁇ m, preferably 2-5 ⁇ m).
  • MMD mass median diameter
  • a salt of the invention is suitably provided in particulate form, particularly in the form of a micronised or spray-dried product.
  • the particle size of the excipient will be much greater than the salt of the invention.
  • the excipient is lactose it will typically be present as milled lactose, wherein at least 85% of lactose particles have a MMD of 60-90 ⁇ m and not more than 15% have a MMD of less than 15 ⁇ m.
  • Intranasal sprays may be formulated with aqueous or non-aqueous vehicles with the addition of agents such as thickening agents, buffer salts or acid or alkali to adjust the pH, isotonicity adjusting agents or anti-oxidants
  • Preferred unit dosage formulations are those containing an effective dose, as hereinbefore recited, or an appropriate fraction thereof, of the active agent.
  • the formulations of the invention may include other agents conventional in the art having regard to the type of formulation in question.
  • alkaline earth stearates e.g. magnesium stearate
  • Other agents which may e.g. be blended in an amount of 1-10% w/w with lactose, include cellobiose octaacetate as described in WO03/088943.
  • compositions and salts of the invention may also be administered in combination with one or more other pharmaceutically active agents, e.g. for the treatment of respiratory diseases.
  • Such combinations may conveniently be presented in the form of a pharmaceutical formulation and thus pharmaceutical formulations adapted for administration by comprising a combination as defined above together with a physiologically acceptable diluent or carrier is a further aspect of the invention.
  • compositions and salts of the invention and the other pharmaceutically active agents may be administered separately, sequentially or simultaneously in separate or combined pharmaceutical formulations. Appropriate doses of known active agents will be readily appreciated by those skilled in the art.
  • salts of the invention and pharmaceutical formulations thereof have the potential to offer certain advantages over known forms of pharmaceutically active agents for administration by inhalation. Without wishing to be bound by theory it is believed that salts of the invention formed by binding of an active agent to a given polymeric sugar may be expected to result in salts having equivalent physical properties. This should enable all said salts to be formulated in the same way, thus simplifying pharmaceutical development. For inhaled products this has potential benefits for potent ionisable active agents which require low blend strengths as the potency of the drug can be diluted by changing the drug loading on the polymer. The drug/polymer compound can then be micronised and blended with e.g. lactose in the normal way. The need for classical salt selection could also be eliminated thus enabling drugs to be developed more quickly. There is also the potential for both slow release and once daily products and improved drug stability in the presence of carriers such as lactose.
  • the salts of the invention are amorphous and as such there is no opportunity for conversion to other polymorphic forms as may be the case with crystalline forms of active agent; this can be particularly advantageous for dry powder formulations.
  • the amorphous nature of the salts also offers advantages for solution formulations as the salts may dissolve more quickly and / or more predictably than other forms of the active agent.
  • salmeterol hyaluronate according to the invention has desiccant properties such that in a humid environment the particulate material may swell slightly whilst avoiding agglomeration.
  • the salmeterol hyaluronate salt of the invention When blended with a carrier such as lactose the salmeterol hyaluronate salt of the invention appear to inhibit undesired carrier agglomeration and may inhibit adhesion of drug substance to carrier. Hence when blended with a carrier such as lactose the salts of the invention may experience reduced loss of fine particle mass (FPM) on storage especially under humid conditions.
  • FPM fine particle mass
  • Another process for preparing a salt of the invention comprises spray drying a solution (e.g. an aqueous solution) of the active agent and the biodegradable polymeric sugar in the form of its free acid.
  • a solution e.g. an aqueous solution
  • the free acid of the polymeric sugar may be obtained by reaction of a salt, e.g. a sodium salt, of the sugar with a strong acid, e.g. HCI, prior to reaction with the active agent. A reduction in molecular weight is expected during this process.
  • a salt e.g. a sodium salt
  • HCI strong acid
  • Figure 1 shows the 13C CP-MAS solid-state NMR spectra of salmeterol (bottom), hyaluronic acid (top) and salmeterol hyaluronate (middle) prepared according to Example 1.
  • Figure 2 shows the IR spectra of salmeterol (top), hyaluronic acid (bottom) and salmeterol hyaluronate (middle) prepared according to Example 1.
  • Figure 3 shows XRPD profiles for hyaluronic acid (middle), sodium hyaluronate (bottom) and salmeterol hyaluronate (top) (prepared according to Example 1).
  • Figure 4 shows the IR spectra of 4- ⁇ (1f?)-2-[(6- ⁇ 4-[3-
  • Figure 5 shows the IR spectra of salbutamol (top), hyaluronic acid (bottom) ancl salbutamol hyaluronate (middle) prepared according to Example 4.
  • Figure 6 shows the IR spectra of ⁇ /- ⁇ 2-[4-((R)-2-Hydroxy-2- phenylethylamino)phenyl]ethyl ⁇ -(f?)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl) ethylamine (Compound A) free base( top) hyaluronic acid (middle) and Compound A Hyaluronate (bottom)
  • Figure 8 is a bar graph showing the effect on fine particle mass of Compound A hydrochloride (control) and Compound A Hyaluronate following storage at 30°C/65%RH.
  • the measurements represent the mean fine particle mass of the compound deposited in Stage 2 of a reduced Anderson cascade impactor, expressed as ⁇ g (white bars) or % emitted dose (grey bars) and % nominal dose (black bars).
  • the columns represent the following measurements (from left to right): Control at initial timepoint; control after 1 week at 30°C/65%RH, control after 2 weeks at 30°C/65%RH, HA salt at initial timepoint; HA salt after 1 week at 30°C/65%RH, HA salt after 2 weeks at 30°C/65%RH.
  • Figure 7 shows the IR spectra of Compound B free base( top) hyaluronic acid (middle) and Compound B Hyaluronate (bottom)
  • XRPD analysis shown in Figure 1 was performed on a Bruker X-ray powder diffractometer, Model D8 Advance, serial number ROE 2357. The method runs from 2 to 40 degrees 2-Theta with a 0.0145 degree 2-Theta step size and a 1 second collection time at each step.
  • Example 3 The X-ray powder diffraction (XRPD) analysis of Example 3 (shown in Figure 2) was performed on a PANalytical X'Pert Pro powder diffractometer, model PW3040/60, serial number DY1850 using an X'Celerator detector.
  • XRPD X-ray powder diffraction
  • the infrared absorption spectra were recorded at 2 cm-1 resolution over the wavenumber range 4000 to 650 cm-1 using a PerkinElmer Spectrum One FT-IR spectrometer equipped with a PerkinElmer Universal ATR (attenuated total reflection) sampling accessory.
  • the ATR crystal used was a diamond / zinc selenide composite.
  • 1 H NMR spectra were acquired on a 400MHz Bruker DPX400 spectrometer at 300K. Sample was dissolved in CDCI3 or dmso-d6 and chemical shifts were reported in ppm relative to the TMS signal at 0 ppm.
  • the drug was released by dissolving a known weight (10 -100mg) of salt in pH6 buffer (10-10OmI). The released drug was assayed against a standard solution of the drug by HPLC analysis.
  • a drug reference sample 10mg of the free drug was dissolved in acetonitrile/water (10ml) in a volumetric flask and a known volume of this was made up to 1 ml with acetonitrile/water and injected on HPLC (for HPLC conditions see table below).
  • a known quantity of the salt was dissolved in pH6 buffer and a known volume of this solution was injected on HPLC.
  • the loading was determined by comparative HPLC assay. Release of drug from the salt was typically quantitative.
  • HPLC conditions for assay and identification of eluted drug by comparative retention time The following conditions were used for HPLC analysis.
  • Figure 1 shows the 13C CP-MAS solid-state NMR spectra of salmeterol (bottom), hyaluronic acid (top) and the polymeric salt (middle). The resonances of salmeterol are still visible in the polymeric salt but are very broad suggesting that the salmeterol molecule is less mobile than in the pure solid form. This is consistent with the salmeterol molecule being part of a polymeric species.
  • Figure 2 shows the IR spectra of salmeterol (top), hyaluronic acid (bottom) and the polymeric salt (middle). Key features of the spectrum of the polymeric salt indicate that the interaction of salmeterol and hyaluronic acid is via the formation of an amine/carboxylic acid salt, i.e. lack of neutral amine stretch, presence of ionised carboxylate and absence of carboxylic acid functionality.
  • Figure 3 shows XRPD profiles for hyaluronic acid (middle), sodium hyaluronate (bottom) and salmeterol hyaluronate (top). All these traces are characteristic of amorphous substance.
  • Salmeterol hyaluronate prepared as described in Example 1 was micronised using a 4"
  • Blends A and B as tabulated below were prepared by the following procedure:
  • the blends were formulated by placing approximately half of the weighed lactose into a
  • Waring blender All of the drug substance (salmeterol xinafoate or salmeterol hyaluronate) was then added, followed by the remaining lactose.
  • the blender was operated for 5min at the low speed setting.
  • X-ray powder diffraction confirmed that the material remained amorphous after storage.
  • the particle size was measured by laser diffraction using an isooctane/lecithin dispersant.
  • the volume mean diameter increased from 5.9 ⁇ m initially to 7.8 ⁇ m after storage. This small increase is believed to be attributable to swelling as a result of moisture uptake.
  • Thermogravimetric analysis confirmed that the particles had picked up moisture and gravimetric vapour sorption showed that the moisture capacity was around 20% initially. Scanning electron microscopy before and after storage showed no discernable differences.
  • the fine particle fraction measured as percentage Stage 2 deposition of the salmeterol hyaluronate/lactose blends is of the same order as that of the salmeterol xinafoate/lactose blends, but shows far greater stability on storage, with no apparent agglomeration after 1 month at 40°C/75% relative humidity. However, after storage at 40°C/75% relative humidity the salmeterol xinafoate/lactose blend was highly agglomerated and could not be tested.
  • IR spectra of the salt (middle) and comparison with hyaluronic acid (bottom) and original drug substance (top) are shown in Figure 4.
  • Key features of the spectrum of the polymeric salt indicate that the interaction of drug and hyaluronic acid is via the formation of a carboxylic acid salt, i.e. presence of ionised carboxylate and the reduction of carboxylic acid functionality when compared to the spectrum of hyaluronic acid. This would imply that protonation of the secondary amine functionality of the drug has occurred.
  • Salbutamol base (0.5g) was suspended in IMS (22ml), stirred at ca 20-22 0 C to give an almost clear solution.
  • Hyaluronic acid (1g) was added and the suspension was stirred at 20-22°C for 18h.
  • the suspension was filtered, washed with IMS (4 x 50ml) and then with IMS (90ml), pre- warmed to ca 30°C.
  • the solid was dried in vacuo at 20-25 0 C to constant weight to give the product as a white free flowing powder (1.23g, 18.6%w/w loading).
  • the loading and identity of the released drug was confirmed by HPLC analysis using the general method described in Example 1. Release of drug from the salt was typically quantitative.
  • IR spectra of the salt (middle) and comparison with hyaluronic acid (bottom) and original drug substance (top) are shown in Figure 5.
  • Key features of the spectrum of the polymeric salt indicate that the interaction of salbutamol and hyaluronic acid is via the formation of a carboxylic acid salt, i.e. presence of ionised carboxylate and the reduction of carboxylic acid functionality when compared to the spectrum of hyaluronic acid. This would imply that protonation of the secondary amine functionality of salbutamol has occurred.
  • the resinate was spray dried from an aqueous THF solution to provide spray dried drug resinate with particle size of 2 to 5 microns suitable for inhaled application using a Niro Mobile Minor spray drier.
  • the drug loading remained unchanged after spray drying.
  • Each formulation was manufactured as 0.08%w/w (10 ⁇ g/12.5mg lactose) blends.
  • the control formulation comprised micronised Compound A monohydrochloride salt with identical lactose to the hyaluronate formulation (Blend 2) .
  • Blends 1 and 2 as tabulated below were prepared by the following procedure: The blends were manufactured by placing approximately half of the dispensed lactose into a 1 L QMM bowl . The drug substance (Compound A monohydrochloride salt or Compound A hyaluronate) was then added and rinsed with lactose (x3) followed by addition of the remaining lactose. The QMM blender was operated for a total 10min at ⁇ OOrpm. The blending process was stopped briefly after 5 minutes in order to scrape blend off the vessel walls. Table 3
  • Fines represents % v/v of particles less than 15 ⁇ m.
  • HPLC high performance chromatography
  • Hyaluronic acid (48.5g, ) was added to a solution of 2-[(S)-1-(8-methylaminooctyl)- pyrrolidin-3-yl]-2,2-diphenylacetamide (Compound B) (5g) in IMS (300ml) and washed in with IMS (100ml). The white suspension was stirred at 20-25 0 C for 18h. The product was collected by filtration under nitrogen and then washed with IMS (2 x 150ml) under vacuum, then with IMS (2 x 150ml) which was allowed to percolate under gravity and finally with more IMS (2 x 50ml).
  • the washings were monitored for drug content and considered complete once the level of drug in the washes was less than 5mg in a 50ml wash.
  • the washed solid was then dried in vacuo at 3O 0 C for 3h and then 20-25 0 C for 18h and then equilibrated at room temperature for ca 2h to give 46.71 g (14.4%w/w loading as by weight gain) of the resinate as a free flowing white powdery solid.
  • the resinate was spray dried from an aqueous THF solution to provide spray dried drug resinate with particle size of 2 to 5 microns suitable for inhaled application using a Niro Mobile Minor spray drier.
  • the drug loading remained unchanged after spray drying.
  • An excipient preblend was generated by combining the cellobiose and approximately half the lactose into a blending jar and mixing for 5 minutes using a Turbula T2 mixer at 96 rpm. The remaining lactose was transferred to the blending jar and mixed for 2 x 5 minutes at 96 rpm in the Turbula mixer.
  • a drug preblend was prepared by removing approximately half the excipient preblend and adding required drug contents to mixing jar. The jar contents were mixed for 5 minutes at 96rpm. The remaining portion of the excipient preblend was transferred to the mixing jar and mixed for 3 x 5 minutes at 96 rpm in the Turbula mixer. Transfer the blend to an antistatic bag and allow it to equilibrate for 8 hours prior to filling into blister strips. Table 4
  • next generation impactor (NGI-Next Generation lmpactor Consortium), USP, was performed at 60L/min with a DPI device fitted to unit throat. The blends were tested pre and post storage and Compound B base content was quantified by High Performance Liquid chromatography. The results are tabulated below (Table 5).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention a trait à des sels d'un sucre polymérique biodégradable comportant des groupes acides et un agent pharmaceutiquement actif comportant un ou des groupes basiques, et à des formulations pharmaceutiques desdits sels adaptées pour une administration par inhalation.
PCT/EP2005/007991 2004-07-22 2005-07-20 Formulations pharmaceutiques WO2006008173A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0416397.8 2004-07-22
GB0416397A GB0416397D0 (en) 2004-07-22 2004-07-22 Pharmaceutical formulations

Publications (2)

Publication Number Publication Date
WO2006008173A2 true WO2006008173A2 (fr) 2006-01-26
WO2006008173A3 WO2006008173A3 (fr) 2006-05-26

Family

ID=32922634

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/007991 WO2006008173A2 (fr) 2004-07-22 2005-07-20 Formulations pharmaceutiques

Country Status (2)

Country Link
GB (1) GB0416397D0 (fr)
WO (1) WO2006008173A2 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008049842A3 (fr) * 2006-10-26 2008-09-18 Boehringer Ingelheim Int Nouvelles compositions pharmaceutiques pour le traitement de troubles respiratoires et gastro-intestinaux
WO2009087224A1 (fr) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines utilisés en tant qu'inhibiteurs de kinase
EP2286813A2 (fr) 2006-01-31 2011-02-23 Novartis AG Utilisation de dérivés de naphthyridine comme medicaments
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
WO2012034091A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions à titre d'inhibiteurs de trk
WO2012116217A1 (fr) 2011-02-25 2012-08-30 Irm Llc Composés et compositions en tant qu'inhibiteurs de trk
US8399461B2 (en) 2006-11-10 2013-03-19 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for production of same
US8497369B2 (en) 2008-02-07 2013-07-30 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
EP2400950B1 (fr) 2009-02-26 2019-05-22 Glaxo Group Limited Préparations pharmaceutiques comprenant 4-{(1r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]éthoxy}hexyl)amino]-1-hydroxyéthyl}-2-(hydroxyméthyl)-phénol
US11090294B2 (en) 2009-12-01 2021-08-17 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
CN117679423A (zh) * 2022-09-05 2024-03-12 立生医药(苏州)有限公司 预防或治疗呼吸系统疾病的吸入用药物组合物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
JPH1180032A (ja) * 1997-09-12 1999-03-23 Dai Ichi Seiyaku Co Ltd 複合体
DE10064219B9 (de) * 2000-12-22 2009-02-12 Nasalis Pain Relief International Gmbh Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung
US7060691B2 (en) * 2002-10-10 2006-06-13 Giuseppe Petrigni Pharmaceutical colloidal preparation useful in the treatment of respiratory diseases

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2286813A2 (fr) 2006-01-31 2011-02-23 Novartis AG Utilisation de dérivés de naphthyridine comme medicaments
WO2008049842A3 (fr) * 2006-10-26 2008-09-18 Boehringer Ingelheim Int Nouvelles compositions pharmaceutiques pour le traitement de troubles respiratoires et gastro-intestinaux
US8399461B2 (en) 2006-11-10 2013-03-19 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for production of same
WO2009087224A1 (fr) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines utilisés en tant qu'inhibiteurs de kinase
US8497369B2 (en) 2008-02-07 2013-07-30 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
US8772298B2 (en) 2008-02-07 2014-07-08 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
US11116721B2 (en) 2009-02-26 2021-09-14 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol
EP2400950B1 (fr) 2009-02-26 2019-05-22 Glaxo Group Limited Préparations pharmaceutiques comprenant 4-{(1r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]éthoxy}hexyl)amino]-1-hydroxyéthyl}-2-(hydroxyméthyl)-phénol
EP3578169B1 (fr) 2009-02-26 2024-06-26 Glaxo Group Limited Préparations pharmaceutiques comprenant 4-{(1r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]éthoxy}hexyl)amino]-1-hydroxyéthyl}-2-(hydroxyméthyl)-phénol
US11090294B2 (en) 2009-12-01 2021-08-17 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
US12396986B2 (en) 2009-12-01 2025-08-26 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a β-2 adrenoreceptor agonist
WO2012034091A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions à titre d'inhibiteurs de trk
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
WO2012116217A1 (fr) 2011-02-25 2012-08-30 Irm Llc Composés et compositions en tant qu'inhibiteurs de trk
CN117679423A (zh) * 2022-09-05 2024-03-12 立生医药(苏州)有限公司 预防或治疗呼吸系统疾病的吸入用药物组合物

Also Published As

Publication number Publication date
WO2006008173A3 (fr) 2006-05-26
GB0416397D0 (en) 2004-08-25

Similar Documents

Publication Publication Date Title
US12396986B2 (en) Combinations of a muscarinic receptor antagonist and a β-2 adrenoreceptor agonist
AU2020205281B2 (en) Salt of a pyrimido[6,1-a]isoquinolin-4-one compound
US9132121B2 (en) Dry powder formulation comprising a phosphodiesterase inhibitor
WO2010132827A1 (fr) Dextrane à bas poids moléculaire pour inhalations en poudre
WO2006008173A2 (fr) Formulations pharmaceutiques
CA2803418A1 (fr) Formulation de poudre seche comprenant un medicament antimuscarinique
US20110105449A1 (en) Dry powder formulations comprising ascorbic acid derivates
TW200418539A (en) Particulate materials
RU2470639C2 (ru) Композиции для ингаляции, содержащие кислоту монтелукаст и ингибитор pde-4 или ингаляционный кортикостероид
ES2726831T3 (es) Partículas inhalables que comprenden tiotropio e indacaterol
CN105338967A (zh) 包含布地奈德和福莫特罗的药物组合物
KR20170068497A (ko) 티오트로피움, 아미노산 및 산을 함유하는 제형 및 이의 방법
Nyambura Protein formulations for pulmonary delivery
HK1174249B (en) Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
HK1174249A (en) Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase